Therapeutic Targeting Regulatory T Cells in Tumor
作者： Wei Wang , Weiping Zou
DOI: 10.1007/978-94-007-6217-6_25
关键词:
摘要: Cancer cells express a range of tumor associated antigens (TAA) including self-antigens, which should engender TAA-specific immune response to dampen progression and result in eradiation. However, this is rarely happened patients with cancer. It thought that active immunosuppressive network the cancer microenvironment hinders anti-tumor immunity. Regulatory T (Tregs) are an important component suppressive network, suppress cell immunity one main obstacles tempering successful immunotherapy vaccination. In chapter, we focus on Tregs, review their characteristics mechanisms microenvironment, summarize recent development Treg-targeted immunotherapeutic regimens.
springer.com
sci-hub.st 参考文章(143)
Berezhnaya Nm, Interaction between tumor and immune system: the role of tumor cell biology. Experimental Oncology. ,vol. 32, pp. 159- ,(2010)
Masahiro Ohara, Morihito Okada, Yoshiyuki Yamaguchi, Makoto Okawaki, Riki Okita, Dose-Finding Study of Anti-CD25 Antibody for Targeting Regulatory T Cells in Locoregional Immunotherapy of Malignant Effusion Hiroshima journal of medical sciences. ,vol. 57, pp. 37- 46 ,(2008)
Karl-Hermann Schlingensiepen, Birgit Fischer-Blass, Susanne Schmaus, Sylvia Ludwig, Antisense Therapeutics for Tumor Treatment: The TGF-beta2 Inhibitor AP 12009 in Clinical Development Against Malignant Tumors Pancreatic Cancer. ,vol. 177, pp. 137- 150 ,(2008) , 10.1007/978-3-540-71279-4_16
Craig L. Bennett, Jacinda Christie, Fred Ramsdell, Mary E. Brunkow, Polly J. Ferguson, Luke Whitesell, Thaddeus E. Kelly, Frank T. Saulsbury, Phillip F. Chance, Hans D. Ochs, The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genetics. ,vol. 27, pp. 20- 21 ,(2001) , 10.1038/83713
R J North, M Awwad, Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology. ,vol. 65, pp. 87- 92 ,(1988)
Julien Taieb, Nathalie Chaput, Noël Schartz, Stéphan Roux, Sophie Novault, Cédric Ménard, François Ghiringhelli, Magali Terme, Antoine F. Carpentier, Guillaume Darrasse-Jèse, François Lemonnier, Laurence Zitvogel, Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines Journal of Immunology. ,vol. 176, pp. 2722- 2729 ,(2006) , 10.4049/JIMMUNOL.176.5.2722
Amir Sharabi, Nechama Haran Ghera, Breaking Tolerance in a Mouse Model of Multiple Myeloma by Chemoimmunotherapy Advances in Cancer Research. ,vol. 107, pp. 1- 37 ,(2010) , 10.1016/S0065-230X(10)07001-6
K Kondo, R K Gershon, Infectious immunological tolerance. Immunology. ,vol. 21, pp. 903- 914 ,(1971)
Ajay V. Maker, Peter Attia, Steven A. Rosenberg, Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade Journal of Immunology. ,vol. 175, pp. 7746- 7754 ,(2005) , 10.4049/JIMMUNOL.175.11.7746
K. Kondo, R. K. Gershon, Cell interactions in the induction of tolerance: the role of thymic lymphocytes Immunology. ,vol. 18, pp. 723- 737 ,(1970)